Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q4 EPS of ($0.48), $0.02 worse than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.